Use of an SGLT2 inhibitor was associated with more lower limb amputations and nonvertebral fractures in US patients with CKD and type 2 diabetes receiving routine care, but benefits still outweigh risks.
Patients with chronic kidney disease who stop using a class of common blood pressure medications may lower their risk for dialysis, but they also raise their odds of cardiovascular disease, a new study finds.
Effect Of Stopping RAS Inhibitors In Patients With Chronic Kidney Disease by Pooja Shete on January 1, 2021 at 8:08 PM
Certain small studies suggest that a group of medications called RAS inhibitors which are used for the treatment of hypertension, may be harmful in patients with advanced chronic kidney disease. Therefore physicians often stop the treatment with these drugs in such patients.
Research conducted at Karolinska Institutet shows that although stopping RAS inhibitors is linked to a lower risk of requiring dialysis, it is also linked to a higher risk of cardiovascular events, and death.
The research conducted at Karolinska Institutet is published in the
E-Mail
IMAGE: Principal investigator Juan Jesus Carrero, professor at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. view more
Credit: Ulf Sirborn.
Small studies have suggested that a group of medications called RAS inhibitors may be harmful in persons with advanced chronic kidney disease, and physicians therefore often stop the treatment in such patients. Researchers at Karolinska Institutet now show that although stopping the treatment is linked to a lower risk of requiring dialysis, it is also linked to a higher risk of cardiovascular events and death. The results are published in
The Journal of the American Society of Nephrology.
Stopping RAS inhibitors linked to risk of adverse outcomes in patients with chronic kidney disease
Small studies have suggested that a group of medications called RAS inhibitors may be harmful in persons with advanced chronic kidney disease, and physicians therefore often stop the treatment in such patients. Researchers at Karolinska Institutet now show that although stopping the treatment is linked to a lower risk of requiring dialysis, it is also linked to a higher risk of cardiovascular events and death. The results are published in
The Journal of the American Society of Nephrology.
Chronic kidney disease (CKD) affects approximately ten percent of the global population. Hypertension is the most common comorbidity. Patients with CKD have an increased risk of cardiovascular disease and death.